The startup operates a drug discovery platform that employs artificial intelligence to analyze tumor DNA patterns, predicting patient responses to cancer therapies. This enables physicians to make data-driven decisions for personalized treatment in pan-cancer precision medicine.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers exhibit chromosomal instability (CIN), a genomic phenomenon associated with aggressive tumors and poor patient prognosis. Current cancer treatments often lack the precision needed to effectively target cancers with CIN, leading to suboptimal outcomes.
Solution
Tailor Bio is developing a precision medicine platform focused on cancers with chromosomal instability (CIN). The platform leverages a unique understanding of CIN to identify novel therapeutic targets and improve patient stratification. By analyzing tumor DNA patterns, the platform aims to predict patient responses to specific cancer therapies, enabling physicians to make data-driven decisions for personalized treatment strategies. This approach seeks to develop targeted therapies that address the specific characteristics of cancers with CIN, ultimately improving patient outcomes.
Target Audience
The primary target audience includes oncologists, researchers, and pharmaceutical companies focused on developing and implementing precision medicine approaches for cancer treatment.
Features
- AI-driven analysis of tumor DNA to identify CIN patterns
- Prediction of patient response to cancer therapies based on CIN profiles
- Identification of novel therapeutic targets specific to CIN-driven cancers
- Patient stratification tools for more targeted and effective treatments
- Development of targeted therapies for cancers with CIN